香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 建議修訂2025年H股獎勵信託計劃規則 緒言 茲提述(i)本公司日期為2025年3月26日之通函（「通函」）及本公司日期為2025年4 月29日之投票結果公告，內容有關（其中包括）股東於2024年年度股東會上批准 採納2025年H股獎勵信託計劃。2025年H股獎勵信託計劃將2025年計劃受託人透 過市場內交易方式以本公司提供的資金購買的H股作為據此將予授出之獎勵所 涉及的H股。 董事會於2026年3月23日舉行之董事會會議上議決建議修訂2025年H股獎勵信託 計劃。建議修訂2025年H股獎勵信託計劃規則須經股東於2025年年度股東會上 以普通決議案的形式批准後，方可生效。 建議修訂之理由 鑒於資金管理需求，根據2025年H股獎勵信託計劃將予授出之獎勵所涉及之H ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 2026年計劃的目的 2026年計劃目的為： 董事認為，個人績效考核作為獎勵歸屬之條件將有助達致上述目的。 （股份代號：2359） (1) 建議採納2026年H股獎勵信託計劃； 及 (2) 建議授權董事會及╱或授權人士辦理 2026年H股獎勵信託計劃相關事宜 I. 建議採納2026年H股獎勵信託計劃 董事會已於2026年3月23日舉行的董事會會議上議決建議採納2026年計劃。2026 年計劃須經股東於2025年年度股東會批准後，方可生效。根據2026年計劃向選 定參與者授予獎勵需待獎勵函所載由董事會及╱或其授權人士釐定之條件達 成後方會生效。詳情請參閱下文「授予獎勵的條件」一節。2026年計劃的主要條 款載列如下，而建議2026年計劃規則的全文載於本公告附錄。 預期為2026年計劃的潛 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） (1) 建議變更本公司的註冊資本；及 (2) 建議修訂《公司章程》 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）日期為2024年10月 8日、2024年10月21日 及2025年10月10日 的 公 告，內 容 有 關（其 中 包 括）發 行 500,000,000美元於2025年到期之零息有擔保可轉換債券（「債券」）；及(ii)本公司 日期為2025年3月26日的通函（「該通函」）。除非文義另有所指，否則本公告所 用詞彙與該通函所界定者具有相同涵義。 本 公 司 董 事 會（「董事會」）謹 此 宣 佈，於 2026 年 3 月 23 日，第三屆董事會第 二十七次會議議決及批准（其中包括）：(i)建議變更本公司的註冊資本；(ii)建議 修訂《公司章 ...

Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 45,456.2 million, representing a year-on-year increase of 15.8%[2] - The gross profit for the same period was RMB 21,379.1 million, with a gross margin of 47.0%, up from 40.8% in the previous year[2] - Net profit attributable to shareholders reached RMB 19,194.9 million, a significant increase of 105.2% compared to the previous year[2] - The company’s adjusted net profit attributable to shareholders was RMB 14,956.5 million, reflecting a 41.3% increase year-on-year[2] - The company’s basic earnings per share (EPS) increased to RMB 6.72, up 107.4% from RMB 3.24 in the previous year[2] - The overall gross profit increased to RMB 21.38 billion, a 33.5% year-on-year increase, with a gross margin of 47.0%, up 6.2 percentage points from 2024[17] - The adjusted net profit attributable to the parent company for the year ended December 31, 2025, was RMB 19,194.9 million, a significant increase from RMB 9,352.6 million in 2024, representing a growth of 105.5%[36] - The adjusted gross profit for the year ended December 31, 2025, was RMB 21,889.7 million, compared to RMB 16,326.3 million in 2024, reflecting a gross margin increase to 48.2% from 41.6%[36] Revenue Breakdown - Revenue from U.S. clients was RMB 31,250 million, marking a 34.3% increase year-on-year, while revenue from European clients decreased by 4.0% to RMB 4,820 million[7] - The chemical business segment generated RMB 36,465.8 million in revenue, a 25.5% increase from the previous year[9] - WuXi Chemistry's revenue reached RMB 36.47 billion, a year-on-year increase of 25.5%, with over 420,000 new compounds successfully synthesized and delivered to clients in 2025[11] - The small molecule D&M business generated RMB 19.92 billion, growing 11.4% year-on-year, with a total of 3,452 molecules in the pipeline by the end of 2025[11] - TIDES business revenue reached RMB 11.37 billion, a significant year-on-year growth of 96.0%, with a 20.2% increase in orders on hand[11] - The testing business generated RMB 4.04 billion, recovering with a growth of 4.7% year-on-year, while the biology business achieved RMB 2.68 billion, growing 5.2% year-on-year[12] Cash Flow and Investments - Net cash generated from operating activities for the year ending December 31, 2025, was RMB 16,426.3 million, a 37.0% increase from RMB 11,986.8 million for the year ending December 31, 2024.[29] - The net cash used in investing activities decreased by 77.1% to RMB 1,167.4 million for the year ending December 31, 2025, primarily due to significant cash inflows from the sale of shares in WuXi XDC Cayman Inc.[29] - The net cash generated from financing activities was RMB 1,122.7 million for the year ending December 31, 2025, compared to a cash outflow of RMB 3,832.7 million for the year ending December 31, 2024, mainly due to cash inflows from H-share placements.[30] - The company reported a substantial increase in the cash flow from operating activities, which amounted to RMB 16,426.3 million in 2025, compared to RMB 11,986.8 million in 2024, reflecting a growth of 37.8%[38] Dividends and Shareholder Returns - The company proposed a final dividend of RMB 15.7927 per 10 shares, subject to shareholder approval[3] - For the 2024 profit distribution plan, the company will distribute a cash dividend of RMB 9.8169 per 10 shares, totaling RMB 2,832,309,813.65[55] - The special dividend for 2025 will be RMB 3.5000 per 10 shares, amounting to RMB 1,009,797,833.10[56] - The board proposed a cash dividend of RMB 15.7927 per 10 shares for 2025, compared to RMB 9.8169 per 10 shares for 2024, indicating an increase in shareholder returns[151] Operational Efficiency and Business Model - The company continues to enhance its CRDMO business model to provide integrated drug development and manufacturing services globally[5] - The company plans to focus on its unique integrated CRDMO business model, enhancing production efficiency and expanding new capabilities to drive steady business growth[75] - The company aims to improve customer satisfaction through high-quality services and strict intellectual property protection, while expanding its global customer base, particularly targeting long-tail customers[77] - The company aims to enhance its operational efficiency through the application of automation technologies, improving insights into the industry and business predictability[79] Market Position and Growth Prospects - The company is positioned as a global leader in integrated end-to-end new drug R&D services, benefiting from the rapid growth of the global outsourcing market[48] - The company anticipates a continuous increase in outsourcing demand for pharmaceutical research and development, commercial production, and clinical development, necessitating significant capital and resource investment for global capacity and scale expansion[90] - The board expressed confidence in future growth prospects, driven by ongoing product development and market expansion initiatives[112] Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical research services, which could negatively impact its business if industry trends slow down or outsourcing ratios decrease[83][84] - Regulatory changes in the pharmaceutical research services industry pose a risk, as the company must adapt its strategies to comply with evolving policies and regulations[85] - Increased competition in the global pharmaceutical research services market could threaten the company's market position if it fails to strengthen its comprehensive R&D capabilities[86] - Global operations and international policy changes present risks that could adversely affect the company's business continuity and development[88] Corporate Governance and Compliance - The board is committed to high standards of corporate governance, although it has not separated the roles of Chairman and CEO, which is seen as beneficial for management[105] - The company maintains compliance with public shareholding requirements as per listing rules[104] - The company has established a robust internal control system to ensure compliance with laws and regulations, but risks remain if oversight of subsidiaries is insufficient[87] Employee and Operational Metrics - As of December 31, 2025, the company employed 33,834 staff, providing regular training to enhance employee skills and knowledge[94] - Employee costs, including salaries and benefits, rose to RMB 13,731,784 thousand in 2025 from RMB 11,895,755 thousand in 2024, an increase of 15.4%[147]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2026年3月23日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年12月31日止年度全年業績，及建議之末 期股息（如有），以及處理任何其他事項。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2026年3月9日 於本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博 士、詹智玲女士及冷雪松先生。 * 僅供識別 ...

（股份代號：2359） 董事會會議召開日期 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2026年3月23日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2025年12月31日止年度全年業績，及建議之末 期股息（如有），以及處理任何其他事項。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港，2026年3月9日 於本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博 士、詹智玲女士及冷雪松先生。 * 僅供識別 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 本月底法定/註冊股本總額： RMB 2,983,757,155 備註： 第 1 頁 共 11 頁 v 1.2.0 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB ...

Summary of Key Points Core Viewpoint - On February 27, WuXi AppTec conducted a block trade involving 26,000 shares, with a transaction value of 2.5483 million yuan, representing 0.11% of the total trading volume for the day, and the transaction price was 98.01 yuan, which was consistent with the market closing price [1][2]. Group 1 - The block trade involved 26,000 shares of WuXi AppTec [1][2] - The total transaction amount was 2.5483 million yuan [1][2] - The transaction price was 98.01 yuan, unchanged from the market closing price [1][2]

Group 1 - The core viewpoint of the news is that WuXi AppTec's stock has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 7.95% [1][2] - As of February 26, the stock price is reported at 97.85 CNY per share, with a total market capitalization of 291.96 billion CNY [1] - The company has seen a net outflow of 206 million CNY in principal funds, with significant selling pressure compared to buying [1] Group 2 - WuXi AppTec's main business involves a comprehensive platform service for the discovery, development, and production of small molecule chemical drugs, with revenue composition being 78.37% from chemical business, 12.93% from testing, and 6.02% from biological business [2] - The company reported a revenue of 32.857 billion CNY for the first nine months of 2025, reflecting a year-on-year growth of 18.61%, and a net profit of 12.076 billion CNY, up 84.84% [2] - The company has distributed a total of 14.06 billion CNY in dividends since its A-share listing, with 10.406 billion CNY in the last three years [3]